230 related articles for article (PubMed ID: 8503864)
21. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q).
O'Brien DP; Kemball-Cook G; Hutchinson AM; Martin DM; Johnson DJ; Byfield PG; Takamiya O; Tuddenham EG; McVey JH
Biochemistry; 1994 Nov; 33(47):14162-9. PubMed ID: 7947828
[TBL] [Abstract][Full Text] [Related]
22. Molecular determinants involved in differential behaviour between soluble tissue factor and full-length tissue factor towards factor VIIa.
Prasad R; Sen P
Phys Chem Chem Phys; 2017 Aug; 19(33):22230-22242. PubMed ID: 28799584
[TBL] [Abstract][Full Text] [Related]
23. Characterization of porcine factor VII, X and comparison with human factor VII, X.
Chen Y; Qiao J; Tan W; Lu Y; Qin S; Zhang J; Li S; Bu H; Cheng J
Blood Cells Mol Dis; 2009; 43(1):111-8. PubMed ID: 19286401
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of Tissue Factor. Factor VIIa for anticoagulant therapy.
Lazarus RA; Olivero AG; Eigenbrot C; Kirchhofer D
Curr Med Chem; 2004 Sep; 11(17):2275-90. PubMed ID: 15379712
[TBL] [Abstract][Full Text] [Related]
25. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII.
Ruf W; Miles DJ; Rehemtulla A; Edgington TS
J Biol Chem; 1992 Nov; 267(31):22206-10. PubMed ID: 1429572
[TBL] [Abstract][Full Text] [Related]
26. Structural biology of factor VIIa/tissue factor initiated coagulation.
Vadivel K; Bajaj SP
Front Biosci (Landmark Ed); 2012 Jun; 17(7):2476-94. PubMed ID: 22652793
[TBL] [Abstract][Full Text] [Related]
27. Two independent binding sites on monolayers of human endothelial cells are responsible for interaction with coagulation factor VII and factor VIIa.
Reuning U; Preissner KT; Müller-Berghaus G
Thromb Haemost; 1993 Feb; 69(2):197-204. PubMed ID: 8456434
[TBL] [Abstract][Full Text] [Related]
28. III. Instantaneous inhibition by compound 48/80 of tissue factor-initiated extrinsic coagulation is mediated by the downregulation of factor VII activation.
Chu AJ; Wang ZG; Fox MJ
Arch Biochem Biophys; 2000 May; 377(2):357-65. PubMed ID: 10845714
[TBL] [Abstract][Full Text] [Related]
29. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis.
Norledge BV; Petrovan RJ; Ruf W; Olson AJ
Proteins; 2003 Nov; 53(3):640-8. PubMed ID: 14579355
[TBL] [Abstract][Full Text] [Related]
30. Tissue factor pathway.
McVey JH
Baillieres Best Pract Res Clin Haematol; 1999 Sep; 12(3):361-72. PubMed ID: 10856975
[TBL] [Abstract][Full Text] [Related]
31. Large enhancement of functional activity of active site-inhibited factor VIIa due to protein dimerization: insights into mechanism of assembly/disassembly from tissue factor.
Stone MD; Harvey SB; Martinez MB; Bach RR; Nelsestuen GL
Biochemistry; 2005 Apr; 44(16):6321-30. PubMed ID: 15835921
[TBL] [Abstract][Full Text] [Related]
32. Conformational Plasticity-Rigidity Axis of the Coagulation Factor VII Zymogen Elucidated by Atomistic Simulations of the N-Terminally Truncated Factor VIIa Protease Domain.
Madsen JJ; Olsen OH
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33917935
[TBL] [Abstract][Full Text] [Related]
33. Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activity.
Peyvandi F; De Cristofaro R; Akhavan S; Carew JA; Landolfi R; Bauer KA; Mannucci PM
Thromb Haemost; 2002 Nov; 88(5):750-5. PubMed ID: 12428089
[TBL] [Abstract][Full Text] [Related]
34. A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation.
Orning L; Fischer PM; Hu CK; Agner E; Engebretsen M; Husbyn M; Petersen LB; Orvim U; Llinas M; Sakariassen KS
Thromb Haemost; 2002 Jan; 87(1):13-21. PubMed ID: 11848442
[TBL] [Abstract][Full Text] [Related]
35. Peptides corresponding to the second epidermal growth factor-like domain of human blood coagulation factor VII: synthesis, folding and biological activity.
Husbyn M; Orning L; Sakariassen KS; Fischer PM
J Pept Res; 1997 Dec; 50(6):475-82. PubMed ID: 9440049
[TBL] [Abstract][Full Text] [Related]
36. Antibody mapping of tissue factor implicates two different exon-encoded regions in function.
Ruf W; Rehemtulla A; Edgington TS
Biochem J; 1991 Sep; 278 ( Pt 3)(Pt 3):729-33. PubMed ID: 1716883
[TBL] [Abstract][Full Text] [Related]
37. Coagulation factor VII Gln100 --> Arg. Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function.
Kemball-Cook G; Johnson DJ; Takamiya O; Banner DW; McVey JH; Tuddenham EG
J Biol Chem; 1998 Apr; 273(14):8516-21. PubMed ID: 9525966
[TBL] [Abstract][Full Text] [Related]
38. Adipocytes express tissue factor and FVII and are procoagulant in a TF/FVIIa-dependent manner.
Edén D; Panagiotou G; Mokhtari D; Eriksson JW; Åberg M; Siegbahn A
Ups J Med Sci; 2019 Aug; 124(3):158-167. PubMed ID: 31407948
[No Abstract] [Full Text] [Related]
39. The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency.
Peyvandi F; De Cristofaro R; Garagiola I; Palla R; Akhavan S; Landolfi R; Mannucci PM
Br J Haematol; 2004 Dec; 127(5):576-84. PubMed ID: 15566361
[TBL] [Abstract][Full Text] [Related]
40. Purification and properties of human melanoma cell tissue factor.
Siddiqui FA; Amirkhosravi A; Amaya M; Desai H; Meyer T; Francis JL
Clin Appl Thromb Hemost; 2001 Oct; 7(4):289-95. PubMed ID: 11697711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
